Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer

Journal of Clinical Pathology

Volumn 64, Issue 2, 2011, Pages 130-135

  Jones, Robin L ^a   Rojo, Federico ^b,c   A'Hern, Roger ^a   Villena, Nadia ^b   Salter, Janine ^a   Corominas, Josep Maria ^b   Servitja, Sonia ^b   Smith, Ian E ^a   Rovira, Ana ^b   Reis Filho, Jorge S ^d   Dowsett, Mitchell ^a   Albanell, Joan ^b,e  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b HOSPITAL DEL MAR   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; SYNAPTOTAGMIN I;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER GRADING; DATA BASE; DISEASE MARKER; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL NUCLEUS; CHEMOTHERAPY, ADJUVANT; CYTOPLASM; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTOR RELA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79151484029     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.082966     Document Type: Article

References (46)

1. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
2. Biswas DK, Shi Q, Baily S, et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 2004;101:10137-42. (Pubitemid 38891208)
3. Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10. (Pubitemid 37328783)
4. Pianetti S, Arsura M, Romieu-Mourez R, et al. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 2001;20:1287-99. (Pubitemid 32269934)
5. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000;275:8027-31.
6. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? hopes and pitfalls. Nat Rev Drug Discov 2009;8:33-40.
7. Cao Y, Karin M. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003;8:215-23. (Pubitemid 38129943)
8. Bhaumik D, Scott GK, Schokrpur S, et al. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008;27:5643-7.
9. Huber MA, Azoitei N, Baumann B, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114:569-81. (Pubitemid 39572107)
10. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952-60.
11. Gionet N, Jansson D, Mader S, et al. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells. J Cell Biochem 2009;107:448-59.
12. Frasor J, Weaver A, Pradhan M, et al. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 2009;69:8918-25.
13. Zhou Y, Eppenberger-Castori S, Marx C, et al. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 2005;37:1130-44.
14. Zhou Y, Yau C, Gray JW, et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007;7:59.
15. Zhou J, Zhang H, Gu P, et al. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2008;111:419-27.
16. Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer 2007;97:659-69.
17. Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 2006;209:645-52.
18. Merkhofer EC, Cogswell P, Baldwin AS. Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene 2010;29:1238-48.
19. Singh S, Shi Q, Bailey ST, et al. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 2007;6:1973-82.
20. Yamaguchi N, Ito T, Azuma S, et al. Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci 2009;100:1668-74.
21. Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997;272:14914-20.
22. Ho WC, Dickson KM, Barker PA. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaBdependent transcription in cancer cells. Cancer Res 2005;65:4273-81.
23. Bottero V, Busuttil V, Loubat A, et al. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 2001;61:7785-91.
24. Tapia MA, Gonzalez-Navarrete I, Dalmases A, et al. Inhibition of the canonical IKK/ NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 2007;6:2284-92.
25. deGraffenried LA, Chandrasekar B, Friedrichs WE, et al. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 2004;15:885-90.
26. Bednarski BK, Baldwin AS Jr, Kim HJ. Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. PLoS One 2009;4:e6992.
27. van Wijngaarden J, van Beek E, van Rossum G, et al. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer 2007;43:433-42.
28. Montagut C, Tusquets I, Ferrer B, et al. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006;13:607-16.
29. Buchholz TA, Garg AK, Chakravarti N, et al. The nuclear transcription factor kappaB/ bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 2005;11:8398-402. (Pubitemid 41746953)
30. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
31. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
32. Jones RL, Lakhani SR, Ring AE, et al. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 2006;94:358-62.
33. Jones RL, Salter J, A'Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009;116:53-68.
34. Jones RL, Salter J, A'Hern R, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2010;119:315-23.
35. Parton M, Krajewski S, Smith I, et al. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res 2002;8:2100-8. (Pubitemid 34753579)
36. Archer CD, Parton M, Smith IE, et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 2003;89:1035-41. (Pubitemid 37239208)
37. Geyer FC, Lopez-Garcia MA, Lambros MB, et al. Genetic characterisation of breast cancer and implications for clinical management. J Cell Mol Med 2009;13:4090-103.
38. Dajee M, Lazarov M, Zhang JY, et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003;421:639-43. (Pubitemid 36227672)
39. van Hogerlinden M, Rozell BL, Toftgard R, et al. Characterization of the progressive skin disease and inflammatory cell infiltrate in mice with inhibited NF-kappaB signaling. J Invest Dermatol 2004;123:101-8. (Pubitemid 38833470)
40. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, et al. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 1999;59:3299-303.
41. Ricca A, Biroccio A, Trisciuoglio D, et al. relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. Br J Cancer 2001;85:1914-21.
42. Kaltschmidt B, Kaltschmidt C, Hofmann TG, et al. The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur J Biochem 2000;267:3828-35.
43. Ryan KM, Ernst MK, Rice NR, et al. Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000;404:892-7.
44. Sheehy AM, Schlissel MS. Overexpression of RelA causes G1 arrest and apoptosis in a pro-B cell line. J Biol Chem 1999;274:8708-16.
45. Kasibhatla S, Brunner T, Genestier L, et al. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1998;1:543-51.
46. Aleyasin H, Cregan SP, Iyirhiaro G, et al. Nuclear factor-(kappa)B modulates the p53 response in neurons exposed to DNA damage. J Neurosci 2004;24:2963-73.